☆ 4.7 Meeting Abstract

Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).

JOURNAL OF CLINICAL ONCOLOGY (2022)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 40, Issue 6, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/JCO.2022.40.6_suppl.346

Keywords

Funding

BMS
Eisai
EMD Serono
GSK
Ipsen
Pfizer
Merck
Novartis
Roche

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper